Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
One new approach protects CD4 cells against HIV entry, while another snips out viral genes in infected cells.
Different mechanisms suppressed the virus in each person.
Scientists are getting a better sense of the risks and benefits of treatment interruptions in cure research.
After my treatment interruption I’m... undetectable, in every way. Untransmittable, that’s how I’ll stay (hopefully!).
HTI vaccines could become the backbone of a combination approach for achieving a functional cure.
An analysis looked at the way HIV rebounds during treatment interruptions based on the age of the antiretrovirals used.
This raises concerns that men with HIV participating in cure and therapeutic vaccine studies may transmit the virus.
A new study found that 44% of Medicaid enrollees with HIV who stopped antiretroviral treatment did not restart therapy within 18 months.
According to a survey, many people with HIV don’t understand how cure trials work.
A new study found that 44% of such individuals who stopped antiretroviral treatment did not restart therapy within 18 months.
Previous research has shown that long interruptions are not safe—but what about shorter, more closely monitored gaps in treatment?
Many HIV cure trials take participants off antiretrovirals for a period in order to see how well the investigational treatment works.
This raises the risk of transmitting the virus while interrupting treatment as part of a study.
Post-HIV-treatment viral control is more likely in those treated very early.
Periodic infusions of such antibodies may eventually become a new way of treating the virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.